by The plasma protein therapeutics market size is poised to grow by USD 44.01 billion by 2032 from USD 28.13 billion in 2023, exhibiting a CAGR of 5.10% during the forecast period 2023-2032.
Key Takeaways
- North America contributed more than 47% of revenue share in 2022.
- Asia-Pacific is estimated to expand the fastest CAGR between 2023 and 2032.
- By product type, the immunoglobulin segment has held the largest market share of 35% in 2022.
- By product type, the albumin segment is anticipated to grow at a remarkable CAGR of 6.5% between 2023 and 2032.
- By application, the hemophilia segment generated over 32% of revenue share in 2022.
- By application, the primary immunodeficiency disorder segment is expected to expand at the fastest CAGR over the projected period.
- By end user, the hospitals segment generated over 70% of revenue share in 2022.
- By end user, the other segment is expected to expand at the fastest CAGR over the projected period.
The plasma protein therapeutics market encompasses a dynamic landscape driven by the increasing demand for therapeutic proteins derived from human plasma. This market is primarily fueled by the rising prevalence of chronic diseases, including immunodeficiency disorders and hemophilia. The escalating awareness regarding plasma-derived therapies, coupled with advancements in biotechnology, has significantly contributed to the sector’s growth.
Growth Factors
The market’s growth is propelled by the expanding applications of plasma protein therapeutics across various medical conditions. Innovations in manufacturing processes, ensuring product safety and efficacy, further stimulate market expansion. Additionally, the growing geriatric population and increased healthcare expenditure play pivotal roles in driving demand.
Get a Sample: https://www.precedenceresearch.com/sample/3630
Plasma Protein Therapeutics Market Scope
| Report Coverage | Details |
| Growth Rate from 2023 to 2032 | CAGR of 5.10% |
| Market Size in 2023 | USD 28.13 Billion |
| Market Size by 2032 | USD 44.01 Billion |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Product Type, By Application, and By End-user |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Region Snapshot
Drivers:
Key drivers include the escalating incidence of rare diseases, creating an urgent need for specialized treatments. Furthermore, the approval and commercialization of novel plasma protein therapeutics contribute significantly to market acceleration. The increasing adoption of these therapies in hospitals and specialty clinics further propels the market forward.
Challenges:
The industry faces challenges such as stringent regulatory requirements, which can impact the timely approval and market entry of new therapies. Additionally, the high cost associated with plasma protein therapeutics poses a challenge to accessibility, particularly in developing regions.
Opportunities:
Amidst the challenges, opportunities lie in technological advancements, enabling more cost-effective production methods. Collaborations between pharmaceutical companies and research institutions open avenues for innovative therapeutic solutions. Furthermore, the untapped potential in emerging markets provides a promising landscape for market players.
Read Also: Radar Sensors Market Size To Rake USD 39.37 Bn By 2032
Plasma Protein Therapeutics Market Players
- CSL Limited
- Grifols S.A.
- Takeda Pharmaceutical Company Limited
- Octapharma AG
- Biotest AG
- Kedrion S.p.A.
- Shire (acquired by Takeda)
- Bio Products Laboratory (BPL)
- Kamada Ltd.
- China Biologic Products Holdings, Inc.
- Octapharma Plasma, Inc.
- Sanquin
- LFB S.A.
- ADMA Biologics, Inc.
- Bioverativ (acquired by Sanofi)
Segments Covered in the Report
By Product Type
- Immunoglobulin
- Albumin
- Plasma derived factor VIII
- Others
By Application
- Hemophilia
- Idiopathic thrombocytopenic purpura
- Primary immunodeficiency disorder
- Others
By End-user
- Hospitals
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Plasma Protein Therapeutics Market
5.1. COVID-19 Landscape: Plasma Protein Therapeutics Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Plasma Protein Therapeutics Market, By Product Type
8.1. Plasma Protein Therapeutics Market Revenue and Volume, by Product Type, 2023-2032
8.1.1 Immunoglobulin
8.1.1.1. Market Revenue and Volume Forecast (2020-2032)
8.1.2. Albumin
8.1.2.1. Market Revenue and Volume Forecast (2020-2032)
8.1.3. Plasma derived factor VIII
8.1.3.1. Market Revenue and Volume Forecast (2020-2032)
8.1.4. Others
8.1.4.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 9. Global Plasma Protein Therapeutics Market, By Application
9.1. Plasma Protein Therapeutics Market Revenue and Volume, by Application, 2023-2032
9.1.1. Hemophilia
9.1.1.1. Market Revenue and Volume Forecast (2020-2032)
9.1.2. Idiopathic thrombocytopenic purpura
9.1.2.1. Market Revenue and Volume Forecast (2020-2032)
9.1.3. Primary immunodeficiency disorder
9.1.3.1. Market Revenue and Volume Forecast (2020-2032)
9.1.4. Others
9.1.4.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 10. Global Plasma Protein Therapeutics Market, By End-user
10.1. Plasma Protein Therapeutics Market Revenue and Volume, by End-user, 2023-2032
10.1.1. Hospitals
10.1.1.1. Market Revenue and Volume Forecast (2020-2032)
10.1.2. Others
10.1.2.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 11. Global Plasma Protein Therapeutics Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
11.1.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.1.3. Market Revenue and Volume Forecast, by End-user (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
11.1.4.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.1.4.3. Market Revenue and Volume Forecast, by End-user (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
11.1.5.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.1.5.3. Market Revenue and Volume Forecast, by End-user (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
11.2.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.2.3. Market Revenue and Volume Forecast, by End-user (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
11.2.4.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.2.4.3. Market Revenue and Volume Forecast, by End-user (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
11.2.5.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.2.5.3. Market Revenue and Volume Forecast, by End-user (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
11.2.6.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.2.6.3. Market Revenue and Volume Forecast, by End-user (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
11.2.7.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.2.7.3. Market Revenue and Volume Forecast, by End-user (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
11.3.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.3.3. Market Revenue and Volume Forecast, by End-user (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
11.3.4.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.3.4.3. Market Revenue and Volume Forecast, by End-user (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
11.3.5.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.3.5.3. Market Revenue and Volume Forecast, by End-user (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
11.3.6.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.3.6.3. Market Revenue and Volume Forecast, by End-user (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
11.3.7.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.3.7.3. Market Revenue and Volume Forecast, by End-user (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
11.4.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.4.3. Market Revenue and Volume Forecast, by End-user (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
11.4.4.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.4.4.3. Market Revenue and Volume Forecast, by End-user (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
11.4.5.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.4.5.3. Market Revenue and Volume Forecast, by End-user (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
11.4.6.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.4.6.3. Market Revenue and Volume Forecast, by End-user (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
11.4.7.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.4.7.3. Market Revenue and Volume Forecast, by End-user (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
11.5.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.5.3. Market Revenue and Volume Forecast, by End-user (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
11.5.4.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.5.4.3. Market Revenue and Volume Forecast, by End-user (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
11.5.5.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.5.5.3. Market Revenue and Volume Forecast, by End-user (2020-2032)
Chapter 12. Company Profiles
12.1. CSL Limited
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Grifols S.A.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Takeda Pharmaceutical Company Limited
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Octapharma AG
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Biotest AG
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Kedrion S.p.A.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Shire (acquired by Takeda)
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Bio Products Laboratory (BPL)
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Kamada Ltd.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. China Biologic Products Holdings, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.uswebwire.com/
